Navigation Links
Pharmaceutical Benefits Scheme Extended for 2 Novel Breast Cancer Drugs

Two new drugs to battle breast cancer have made their way into the Pharmaceutical Benefits Scheme which is a succor for the multitude of sufferers//, who can now avail superior treatment notwithstanding the cost of drugs. This is good news as breast cancer carries the ignominy of being the most common cancer befalling women, affecting 14,000 people annually.

The drugs are targeted at post-menopausal women suffering hormone-dependant early breast cancer, who will be in a position to avail the drug from December 1.

Breast Cancer Network Australia CEO Lyn Swinburne explained that the drugs, called as aromatase inhibitors, were consumed by more than 50% of women suffering breast cancer. Ms Swinburne said "It is important these drugs are on the PBS because they offer women choice. Women shouldn't have to worry about the cost; they have enough decisions to make and options to consider without the added worry of how they are going to pay for these things. What we want is the best treatment for the individual woman to ensure she has the best chance of recovery."

National Breast Cancer Centre acting deputy director Dr Alison Evans said, "Their listing on the PBS is wonderful news as it provides additional treatment options for patients with early breast cancer."


'"/>




Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Medicis Pharmaceutical company enters pediatric market
4. Pharmaceutical companies are targeting patients
5. FDA approves Watson Pharmaceuticals Oxytrol patch
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
8. Pharmaceutical industries grant for R&D to be monitored
9. Japanese And Chinese Pharmaceutical Companies Join Together In Drug Testing
10. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... of thousands of defective respirators, according to court documents and SEC filings. ... William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology: